Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical Isolates

The integrase inhibitor raltegravir (RAL) is currently used for the treatment of both treatment-naïve and treatment-experienced HIV-1-infected patients. Elvitegravir (EVG) is in late phases of clinical development. Since significant cross-resistance between RAL and EVG is observed, there is a need f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Van Wesenbeeck, L., Rondelez, E., Feyaerts, M., Verheyen, A., Van der Borght, K., Smits, V., Cleybergh, C., De Wolf, H., Van Baelen, K., Stuyver, L. J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology (ASM) 2011
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3019647/
https://ncbi.nlm.nih.gov/pubmed/20956600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01733-09
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados